U.S. Food And Drug Administration Accepts Supplemental Biologics License Application For Subcutaneous Formulation Of ORENCIA® (abatacept)
Links shared publicly online about this topic.
- 667total visits
U.S. Food And Drug Administration Accepts Supplemental Biologics License Application For Subcutaneous Formulation Of ORENCIA® (abatacept)
Bristol-Myers Squibb Company (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for the subcutaneous
View full resource at medicalnewstoday.com
Tags: Rheumatoid Arthritis Medication, Drug, FDA, Orencia, Bristol-Myers Squibb
Most Recently Shared on December 10, 2010 at 5:05 am By:
U.S. Food And Drug Administration Accepts Supplemental Biologics License Application For Subcutaneous Formulation Of O... http://mnt.to/3NPD
Also Shared By:
Advertisement
MNT Arthritis News
@mnt_arthritis
U.S. Food And Drug Administration Accepts Supplemental Biologics License Application For Subcutaneous Formulation Of O... http://mnt.to/3NPD
1 year ago...